AMRX vs MSCI · P/E 44, rev $1.52B vs P/E 37, rev $1.72B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus MSCI Inc (MSCI) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
MSCI Inc (MSCI) is a financial data & stock exchanges company listed on US.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported MSCI revenue for 2026-06-30 was $1.72B. Net income was $748.0M. MSCI currently screens at market cap $46.82B and trailing P/E 36.8.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. MSCI currently screens at market cap $46.82B and trailing P/E 36.8.
Not investment advice. Open the AMRX and MSCI stock pages for the full models.
Not investment advice.